NasdaqGM - Nasdaq Real Time Price USD

iTeos Therapeutics, Inc. (ITOS)

6.55

+0.11

+(1.71%)

As of 2:21:05 PM EDT. Market Open.

Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?

The consensus price target hints at a 211.1% upside potential for iTeos Therapeutics (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 6 days ago

ITOS
+1.71%
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash balance and investment balance of $624.3 million as of March 31, 2025 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and developm

GlobeNewswire 9 days ago

ITOS
+1.71%
Positive week for iTeos Therapeutics, Inc. (NASDAQ:ITOS) institutional investors who lost 38% over the past year

Key Insights Given the large stake in the stock by institutions, iTeos Therapeutics' stock price might be vulnerable to...

Simply Wall St. 19 days ago

ITOS
+1.71%
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual

GlobeNewswire last month

ITOS
+1.71%
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet

The consensus price target hints at a 212.5% upside potential for iTeos Therapeutics (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks last month

ITOS
+1.71%
iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations

iTeos Therapeutics ( NASDAQ:ITOS ) Full Year 2024 Results Key Financial Results Revenue: US$35.0m (up 178% from FY...

Simply Wall St. 2 months ago

ITOS
+1.71%
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025- Completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial- EOS-215 Phase 1 trial TRM-010 patient enrollment anticipated to begin in 2Q25- Cash balance and investment balance of $655.0 million as of December 31, 2024 expected to provide runway through 2027 WATERTOWN

GlobeNewswire 2 months ago

ITOS
+1.71%
We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 3 months ago

ITOS
+1.71%
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy

iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 3 months ago

ITOS
+1.71%
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

- Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - EOS-984 Phase 1 monotherapy and PD-1 combination data anticipated in 2H25 - EOS-215, a potential best-in-class anti-TREM2 monoclonal antibody, IND submission anticipated in 1Q25 - Cash balance and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 WAT

GlobeNewswire 3 months ago

ITOS
+1.71%
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 15, 2025 at 7:30 AM PST (10:30

GlobeNewswire 3 months ago

ITOS
+1.71%
iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo

Wells Fargo lowered the firm’s price target on iTeos Therapeutics (ITOS) to $19 from $31 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended b

TipRanks 4 months ago

ITOS
+1.71%
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy

iTeos' Phase II trial for inupadenant met its primary and secondary endpoints but offered little more than existing treatments.

Clinical Trials Arena 4 months ago

ITOS
+1.71%
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts- Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS- Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed- Inupadenant deprioritized to

GlobeNewswire 4 months ago

ITOS
+1.71%
iTeos to Participate in Upcoming Investor Conferences

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December: 7Th Annual Evercore HealthCONx ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: Tuesday, December 3, 2024Time: 9:35

GlobeNewswire 5 months ago

ITOS
+1.71%
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Last week, you might have seen that iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) released its third-quarter result to the...

Simply Wall St. 5 months ago

ITOS
+1.71%
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO- Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination- Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful

GlobeNewswire 5 months ago

ITOS
+1.71%
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that preclinical, translational, and clinical data from inupadenant will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2024, being held December 11-13, 2024 in G

GlobeNewswire 6 months ago

ITOS
+1.71%
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.

Investor's Business Daily 7 months ago

NUVL

ITOS
+1.71%
ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm.

Pharmaceutical Technology 7 months ago

ITOS
+1.71%

Performance Overview

Return	ITOS	S&P 500 (^GSPC)
YTD	-14.71%	-3.03%
1-Year	-46.31%	+9.94%
3-Year	-74.10%	+38.32%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

iTeos Therapeutics, Inc. (ITOS)

Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

Positive week for iTeos Therapeutics, Inc. (NASDAQ:ITOS) institutional investors who lost 38% over the past year

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet

iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully

All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo

Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

iTeos to Participate in Upcoming Investor Conferences

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

Performance Overview